751 related articles for article (PubMed ID: 27270872)
1. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.
Rahmani S; Asgary S; Askari G; Keshvari M; Hatamipour M; Feizi A; Sahebkar A
Phytother Res; 2016 Sep; 30(9):1540-8. PubMed ID: 27270872
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial.
Panahi Y; Kianpour P; Mohtashami R; Jafari R; Simental-Mendía LE; Sahebkar A
Drug Res (Stuttg); 2017 Apr; 67(4):244-251. PubMed ID: 28158893
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.
Mirhafez SR; Azimi-Nezhad M; Dehabeh M; Hariri M; Naderan RD; Movahedi A; Abdalla M; Sathyapalan T; Sahebkar A
Adv Exp Med Biol; 2021; 1308():25-35. PubMed ID: 33861434
[TBL] [Abstract][Full Text] [Related]
4. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial.
Panahi Y; Kianpour P; Mohtashami R; Jafari R; Simental-Mendía LE; Sahebkar A
J Cardiovasc Pharmacol; 2016 Sep; 68(3):223-9. PubMed ID: 27124606
[TBL] [Abstract][Full Text] [Related]
5. Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial.
Saberi-Karimian M; Keshvari M; Ghayour-Mobarhan M; Salehizadeh L; Rahmani S; Behnam B; Jamialahmadi T; Asgary S; Sahebkar A
Complement Ther Med; 2020 Mar; 49():102322. PubMed ID: 32147075
[TBL] [Abstract][Full Text] [Related]
6. Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Mirhafez SR; Farimani AR; Dehhabe M; Bidkhori M; Hariri M; Ghouchani BF; Abdollahi F
J Gastrointestin Liver Dis; 2019 Jun; 28():183-189. PubMed ID: 31204416
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of curcumin plus piperine co-supplementation in moderate-to-high hepatic steatosis: A double-blind, randomized, placebo-controlled clinical trial.
Sharifi S; Bagherniya M; Khoram Z; Ebrahimi Varzaneh A; Atkin SL; Jamialahmadi T; Sahebkar A; Askari G
Phytother Res; 2023 Jun; 37(6):2217-2229. PubMed ID: 36799355
[TBL] [Abstract][Full Text] [Related]
8. Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial.
Panahi Y; Valizadegan G; Ahamdi N; Ganjali S; Majeed M; Sahebkar A
J Cell Biochem; 2019 Sep; 120(9):15989-15996. PubMed ID: 31168845
[TBL] [Abstract][Full Text] [Related]
9. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
[TBL] [Abstract][Full Text] [Related]
10. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease.
Saadati S; Hatami B; Yari Z; Shahrbaf MA; Eghtesad S; Mansour A; Poustchi H; Hedayati M; Aghajanpoor-Pasha M; Sadeghi A; Hekmatdoost A
Eur J Clin Nutr; 2019 Mar; 73(3):441-449. PubMed ID: 30610213
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
Chen S; Zhao X; Ran L; Wan J; Wang X; Qin Y; Shu F; Gao Y; Yuan L; Zhang Q; Mi M
Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
[TBL] [Abstract][Full Text] [Related]
12. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Faghihzadeh F; Adibi P; Hekmatdoost A
Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
[TBL] [Abstract][Full Text] [Related]
13. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
Nutr Metab (Lond); 2019; 16():8. PubMed ID: 30705687
[TBL] [Abstract][Full Text] [Related]
14. The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Jalali M; Mahmoodi M; Mosallanezhad Z; Jalali R; Imanieh MH; Moosavian SP
Complement Ther Med; 2020 Jan; 48():102283. PubMed ID: 31987259
[TBL] [Abstract][Full Text] [Related]
15. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial.
Cicero AFG; Sahebkar A; Fogacci F; Bove M; Giovannini M; Borghi C
Eur J Nutr; 2020 Mar; 59(2):477-483. PubMed ID: 30796508
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Yang K; Chen J; Zhang T; Yuan X; Ge A; Wang S; Xu H; Zeng L; Ge J
Front Immunol; 2022; 13():949746. PubMed ID: 36159792
[TBL] [Abstract][Full Text] [Related]
17. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials.
Goodarzi R; Sabzian K; Shishehbor F; Mansoori A
Phytother Res; 2019 Mar; 33(3):561-570. PubMed ID: 30653773
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol.
Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
BMJ Open; 2017 Jul; 7(7):e016914. PubMed ID: 28698350
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial.
Panahi Y; Kianpour P; Mohtashami R; Atkin SL; Butler AE; Jafari R; Badeli R; Sahebkar A
Phytother Res; 2018 Jul; 32(7):1382-1387. PubMed ID: 29520889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
